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A bs tr ac t
Background
The use of valproic acid in the first trimester of pregnancy is associated with an in-
creased risk of spina bifida, but data on the risks of other congenital malformations 
are limited.
Methods
We first combined data from eight published cohort studies (1565 pregnancies in 
which the women were exposed to valproic acid, among which 118 major malfor-
mations were observed) and identified 14 malformations that were significantly more 
common among the offspring of women who had received valproic acid during the 
first trimester. We then assessed the associations between use of valproic acid during 
the first trimester and these 14 malformations by performing a case–control study 
with the use of the European Surveillance of Congenital Anomalies (EUROCAT) 
antiepileptic-study database, which is derived from population-based congenital-
anomaly registries. Registrations (i.e., pregnancy outcomes with malformations 
included in EUROCAT) with any of these 14 malformations were compared with 
two control groups, one consisting of infants with malformations not previously 
linked to valproic acid use (control group 1), and one consisting of infants with 
chromosomal abnormalities (control group 2). The data set included 98,075 live 
births, stillbirths, or terminations with malformations among 3.8 million births in 
14 European countries from 1995 through 2005.
Results
Exposure to valproic acid monotherapy was recorded for a total of 180 registrations, 
with 122 registrations in the case group, 45 in control group 1, and 13 in control 
group 2. As compared with no use of an antiepileptic drug during the first trimes-
ter (control group 1), use of valproic acid monotherapy was associated with signifi-
cantly increased risks for 6 of the 14 malformations under consideration; the ad-
justed odds ratios were as follows: spina bifida, 12.7 (95% confidence interval [CI], 
7.7 to 20.7); atrial septal defect, 2.5 (95% CI, 1.4 to 4.4); cleft palate, 5.2 (95% CI, 2.8 
to 9.9); hypospadias, 4.8 (95% CI, 2.9 to 8.1); polydactyly, 2.2 (95% CI, 1.0 to 4.5); 
and craniosynostosis, 6.8 (95% CI, 1.8 to 18.8). Results for exposure to valproic acid 
were similar to results for exposure to other antiepileptic drugs.
Conclusions
The use of valproic acid monotherapy in the first trimester was associated with sig-
nificantly increased risks of several congenital malformations, as compared with no 
use of antiepileptic drugs or with use of other antiepileptic drugs.
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Valproic acid, which has been used for the treatment of seizure for more than 30 years, has long been recognized as a 
teratogen. Maternal exposure to valproic acid 
monotherapy during the first trimester was first 
linked to an increased risk of congenital spina 
bifida in the 1980s1-6; subsequent studies con-
firmed this increased risk and also suggested 
increased risks of other major congenital malfor-
mations.7,8 Recently, the American Academy of 
Neurology recommended avoidance of valproic acid 
during pregnancy if possible.9 However, if treat-
ment with valproic acid has been providing good 
seizure control, it can be difficult to change the 
drug before or during pregnancy.10,11
Although a number of cohort studies of wom-
en exposed to valproic acid in pregnancy have 
shown an association with a range of malforma-
tions,12-17 these studies have had limited power 
individually to detect excess risks of specific mal-
formations. For rare outcomes, such as these spe-
cific malformations, large population-based case–
control studies are more appropriate.18
We combined the data from cohort studies to 
identify indications that malformations were oc-
curring at greater frequency than expected among 
offspring exposed to valproic acid during the first 
trimester of pregnancy. We then conducted a 
population-based, case–control study to test our 
hypotheses, using the antiepileptic-study database 
established by European Surveillance of Congeni-
tal Anomalies (EUROCAT).
Me thods
EUROCAT Database
We used the EUROCAT antiepileptic-study data-
bases, which included data on affected live births, 
stillbirths, fetal deaths after 20 or more weeks of 
gestation, and terminations of pregnancy after 
prenatal diagnosis for the years 1995 through 
2005 from 19 population-based EUROCAT regis-
tries in 14 countries (for more information, see 
Section 1 of the Supplementary Appendix, avail-
able with the full text of this article at NEJM 
.org).19 The study sample consisted of 3,881,592 
live births and stillbirths, of which 98,075 in-
volved a major congenital malformation.
The standard data recorded for each registra-
tion are described in EUROCAT Guide 1.3.20 Mul-
tiple sources are used to ascertain pregnancy out-
comes with malformations (registrations).21 Data 
are managed in a standard software program that 
is used by all registries and includes error checks.20 
Infants or fetuses having only malformations cat-
egorized as minor according to EUROCAT defini-
tions were excluded.20 One syndrome and up to 
eight malformations are coded with International 
Classification of Diseases, Ninth Revision (ICD-9) or 
International Classification of Diseases, Tenth Revision 
(ICD-10) codes, with British Pediatric Association 
(BPA) one-digit extensions. These codes are re-
grouped into the standard EUROCAT malforma-
tion subgroups.20 Maternal illness before and 
during pregnancy (ICD-9 or ICD-10 code plus de-
scriptive information) and drug exposure in the 
first trimester of pregnancy (descriptive informa-
tion or Anatomical Therapeutic Chemical [ATC] 
code22) are recorded. The first trimester is defined 
as the period from the first day of the last men-
strual period through the 12th week of gestation.
Ascertainment of Exposure
Information on maternal antiepileptic-drug ex-
posure is mainly obtained from medical hospital 
records generated during pregnancy (for all 19 reg-
istries). Five registries also use other prospective-
ly recorded sources of information (records from 
general practitioners, pharmacy records, and medi-
cal records held by the patient), and three regis-
tries use a structured interview or questionnaire 
after birth to acquire additional information on 
drug exposure. The persons who recorded infor-
mation in registries were not aware of the specific 
hypothesis of the study. Antiepileptic drugs are 
available by prescription only and are typically 
supplied for long-term use; thus, medical records 
were considered to be a good source of data for 
ascertainment of exposure.
To be included in the EUROCAT antiepileptic-
study database, a registry must have recorded a 
diagnosis of maternal epilepsy or antiepileptic-
drug exposure for at least 3 registrations per 1000 
(to exclude registries with low rates of exposure 
ascertainment) and must have recorded a com-
plete drug name or ATC code for at least 80% of 
all pregnancies exposed to antiepileptic drugs 
throughout the study period (to exclude registries 
with incomplete data on exposure to antiepilep-
tic drugs).
Study Design
We searched PubMed, Web of Science, and Em-
base for studies addressing exposure to valproic 
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acid in pregnancy. Eight cohort studies met the 
inclusion criteria and were included in the review 
(see Section 2 in the Supplementary Appendix for 
a description of the inclusion criteria).12-17,23,24 
These eight studies included 1565 pregnancy out-
comes in which there was exposure to valproic 
acid monotherapy during the first trimester; in 
118 of these outcomes there was a major con-
genital malformation as defined by EUROCAT. The 
overall rate of major congenital malformations 
was 7.5% (95% confidence interval [CI], 6.3 to 9.0) 
(Table 1).
All 14 malformations with prevalences that were 
significantly higher in the studies of maternal 
exposure to valproic acid than in the EUROCAT 
reference group (of 3.8 million) (P<0.05) were 
included in the case–control study. The number 
of cases with each of these 14 malformations is 
detailed in Section 2 in the Supplementary Ap-
pendix.
To minimize the chances that we missed a 
group that warranted inclusion by looking only 
at cohort studies in the literature review, we also 
searched case–control studies. The one additional 
group we found — limb-reduction malforma-
tions25,26 — was excluded to avoid a possible un-
derestimation in the case–control analyses; we 
examined the group with limb-reduction malfor-
mations separately. 
We used the EUROCAT antiepileptic-study data-
base to compare the odds of exposure to valproic 
acid monotherapy among cases (for each of the 
14 malformations identified from the literature 
review) with the odds of exposure in two groups 
of controls — a group with major malformations 
other than those under study and a group with 
malformations associated with chromosomal ab-
normalities. Exposure to valproic acid monother-
apy during the first trimester was compared with 
the absence of exposure to antiepileptic drugs 
and with exposure to an antiepileptic-drug mono-
therapy other than valproic acid.
Cases were defined as all live births, fetal 
deaths after at least 20 weeks of gestation, and 
terminations of pregnancy after prenatal diag-
nosis with at least one of the following malfor-
mations: spina bifida, microcephaly, ventricular 
septal defect, atrial septal defect, tetralogy of 
Fallot, pulmonary-valve atresia, hypoplastic right 
heart, cleft palate (without associated cleft lip), 
diaphragmatic hernia, gastroschisis, hypospadias, 
clubfoot, polydactyly, and craniosynostosis. All 
Table 1. Overview of Studies Included in the Analysis.
Study Country Birth Years Included
First-Trimester Exposure to Valproic  
Acid Monotherapy
Exposed 
Pregnancies
Births with 
Malformation
Malformation  
Rate 
number % (95% CI)
Samrén et al.14 Germany, Finland,  
and the Netherlands
1972–1990 184 16 8.7 (5.4–13.7)
Kaaja et al.24 Finland Jan. 1980–Sept. 1998 61 4 6.6 (2.6–15.7)
Sabers et al.23 Denmark Sept. 1996–May 2000 30 2 6.7 (1.9–21.3)
Vajda et al.15 Australia July 1999–Oct. 2002 89 15 16.9 (10.5–26.0)
Wide et al.16 Sweden July 1995–Dec. 2001 268 26 9.7 (6.7–13.8)
Wyszynski et al.17 United States Feb. 1997–Nov. 2003 149 16 10.7 (6.3–16.8)
Meador et al.12 United Kingdom  
and United States
Oct. 1999–Feb. 2004 69 12 17.4 (10.2–28.0)
Morrow et al.13 United Kingdom Dec. 1996–March 2005 715 44 6.2 (4.6–8.2)
All studies 1972–2005 1565 135 8.6 (7.3–10.1)
All studies, excluding 
minor malforma-
tions*
1972–2005 1565 118 7.5 (6.3–9.0)
* According to the classification of major congenital malformations in the European Surveillance of Congenital Anomalies (EUROCAT) regis-
try, based on the International Classification of Diseases, 10th Edition, 17 malformations were minor and were therefore excluded from the 
analysis. 
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cases with a diagnosed chromosomal or mono-
genic syndrome were excluded.
Control group 1 included live births, fetal 
deaths after 20 weeks or more of gestation, and 
pregnancy terminations after prenatal diagnosis 
that involved major malformations other than the 
14 malformations under study. We excluded chro-
mosomal disorders (the disorders in control 
group 2), as well as identified syndromes (1806 
registrations); cleft lip, cleft lip and palate, or the 
Pierre Robin sequence without a reported cleft 
palate (3382); limb-reduction defects (1704); and 
anencephaly or encephalocele (1759). We also 
excluded five controls for which type of birth 
was unknown. Control group 2 comprised live 
births, fetal deaths after 20 weeks or more of 
gestation, and pregnancy terminations after pre-
natal diagnosis that involved malformations as-
sociated with chromosomal abnormalities. We ex-
cluded two of the entries in this group because 
type of birth was unknown.
All registrations with recorded maternal anti-
epileptic-drug use or maternal epilepsy were se-
lected, verified by the registry, and coded accord-
ing to the name of the antiepileptic drug. After 
verification, 99.9% of the antiepileptic drugs to 
which mothers were exposed in the first trimes-
ter of pregnancy had been identified. To mini-
mize the risk of misclassification, we excluded 
all registrations for which there had been a pre-
vious diagnosis of maternal epilepsy but for which 
there was no history of maternal antiepileptic-drug 
use in the first trimester (a total of 96 cases, 122 
controls in group 1, and 19 controls in group 2).
Statistical Analysis
Logistic-regression analysis was used to calculate 
odds ratios with Stata software, version 10. Crude 
odds ratios were calculated for all registries, in-
cluding those without records of valproic acid ex-
posure. Odds ratios were adjusted for maternal 
age (categorized as less than 25 years, 25 to 29 
years, 30 to 34 years, or more than 34 years) and 
the child’s year of birth (categorized as being be-
tween 1995 and 1998, between 1999 and 2001, or 
between 2002 and 2005). Odds ratios were also 
adjusted for the individual registry (registries with 
no entries for valproic acid exposure were exclud-
ed) in the comparison of exposure to valproic acid 
monotherapy with no exposure to antiepileptic 
drugs; there were too few controls to make this 
adjustment in other comparisons. For anomalies 
for which there were fewer than six cases with 
exposure to valproic acid, no adjustments were 
made and the exact confidence intervals are pre-
sented.
R esult s
A total of 37,154 cases, 39,472 controls without 
chromosomal abnormalities (control group 1), 
and 11,763 controls with chromosomal abnor-
malities (control group 2) were included in the 
study. The frequency of maternal use of antiepi-
leptic drugs overall in the first trimester of preg-
nancy was 5.7 per 1000 registrations, and the 
frequency of maternal use of valproic acid spe-
cifically was 2.0 per 1000. The frequency of expo-
sure to valproic acid was three times as high 
among cases (3.3 per 1000 registrations) as among 
controls in both groups (1.1 per 1000) (Table 2).
In analyses of cases and the controls in 
group 1, exposure to valproic acid monotherapy 
during the first trimester as compared with no 
exposure to antiepileptic drugs during that period 
was associated with significant increases in the 
risks of spina bifida, atrial septal defect, cleft pal-
ate, hypospadias, polydactyly, and craniosynosto-
sis but not in the risks of microcephaly, tetralogy 
of Fallot, pulmonary-valve atresia, diaphragmatic 
hernia, ventricular septal defect, hypoplastic right 
heart (no exposed cases), gastroschisis, or club-
foot (Table 3). Adjustment for reporting registry, 
birth year of the registration, and maternal age 
did not substantively affect the results (see Sec-
tion 3 in the Supplementary Appendix for details). 
Using the same control group, we found gen-
erally similar associations between valproic acid 
exposure and malformations when valproic acid 
monotherapy was compared with monotherapy 
with another antiepileptic drug — with two ex-
ceptions. When compared with use of another 
antiepileptic drug, valproic acid use was not associ-
ated with a significantly increased risk of cranio-
synostosis but was associated with a significantly 
increased risk of ventricular septal defect.
In corresponding analyses comparing cases 
with the controls in group 2 (those with chromo-
somal abnormalities), the results were generally 
similar. Separate analyses of the suggested asso-
ciation between valproic acid exposure and limb 
reduction showed a significantly increased risk 
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of limb reduction (crude odds ratio, 3.4; 95% CI, 
1.6 to 7.2) as compared with the absence of ex-
posure to antiepileptic drugs.
In control group 1, we also compared the dis-
tribution of malformations among controls ex-
posed to valproic acid with the distribution among 
controls without exposure to antiepileptic drugs 
and found no significant differences (data not 
shown). We found no malformations other than 
those reported in the literature that had a signifi-
cant association with valproic acid exposure in 
this group.
Discussion
In a review of published cohort studies, we iden-
tified 14 major congenital malformations for which 
the risk appeared to be significantly increased in 
association with exposure to valproic acid mono-
therapy during the first trimester of pregnancy as 
compared with no exposure to antiepileptic drugs 
during the first trimester. We then tested these 
indications in a large population-based case− 
control study and found significant associations 
between exposure to valproic acid monotherapy 
in the first trimester (as compared with no ex-
posure to antiepileptic drugs) and six of these 
conditions: spina bifida, atrial septal defect, cleft 
palate, hypospadias, polydactyly, and craniosynos-
tosis. Risks for five of these conditions were 2 to 
7 times as high for exposed fetuses, and the risk 
for the sixth condition, spina bifida, was 12 or 
16 times as high, depending on the control group 
used. We also found an association between limb 
defects and exposure to valproic acid monother-
apy as compared with no exposure to antiepilep-
tic drugs, as suggested in previous case–control 
studies.
Significant associations with valproic acid ex-
posure were noted for five of the six specific 
malformations in analyses comparing exposure 
to valproic acid monotherapy with other antiepi-
leptic-drug monotherapy; an association with 
craniosynostosis was not found. A significant 
association with ventricular septal defect was 
detected, but only for the comparison of cases 
with controls in the group that had malforma-
tions not associated with a chromosomal abnor-
mality — not for the comparison of cases with 
the other control group. Although the observa-
tional nature of this study precludes a conclusion 
about cause and effect, these findings support a 
relationship of these malformations to valproic 
acid specifically rather than to antiepileptic drugs 
Table 2. Exposure to Antiepileptic Drugs in the First Trimester of Pregnancy among Cases and Controls with Congenital 
Malformations.*
Exposure
Cases
(N = 37,154)
Control Group 1
(N = 39,472)
Control Group 2
(N = 11,763)
no.
no./1000  
registrations no.
no./1000 
registrations no.
no./1000  
registrations
No exposure to antiepileptic drugs 36,869 — 39,290 — 11,725 —
Any antiepileptic-drug monotherapy or 
polytherapy
285 7.7 182 4.6 38 3.2
Any antiepileptic-drug monotherapy 223 6.0 155 3.9 32 2.7
Valproic acid monotherapy 122 3.3 45 1.1 13 1.1
Other monotherapy 101† 2.7 110‡ 2.8 19§ 1.6
* Malformations included spina bifida, microcephaly, ventricular septal defect, atrial septal defect, tetralogy of Fallot, pul-
monary-valve atresia, hypoplastic right heart, cleft palate, diaphragmatic hernia, gastroschisis, hypospadias, clubfoot, 
polydactyly, and craniosynostosis.
† Among these patients, 58 received carbamazepine, 21 received lamotrigine, 8 received phenobarbital, 4 received oxcar-
bazepine, 3 received clonazepam, 2 received phenytoin, 1 received methylphenobarbital, 1 received topiramate, and 3 
received unspecified medications.
‡ Among these patients, 65 received carbamazepine, 18 received lamotrigine, 9 received phenobarbital, 7 received oxcar-
bazepine, 3 received phenytoin, 3 received primidone, 2 received clonazepam, 1 received ethosuximide, 1 received 
methylphenobarbital, and 1 received topiramate.
§ Among these patients, 10 received carbamazepine, 4 received phenobarbital, 2 received lamotrigine, 1 received clon-
azepam, 1 received oxcarbazepine, and 1 received phenytoin.
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generally or to underlying epilepsy. Valproic acid is 
used for various indications in European coun-
tries, which means that its use is unlikely to be 
very strongly related to a particular type or sever-
ity of epilepsy. However, we do not have infor-
mation on the type or severity of epilepsy and 
therefore cannot rule out the possibility of con-
founding by indication.
Studies evaluating the risk of general malfor-
mations after in utero exposure to an antiepilep-
Table 3. Odds Ratios for Malformations with Exposure to Valproic Acid Monotherapy as Compared with No Antiepileptic-Drug (AED)
Exposure and with Exposure to Monotherapy with Other Antiepileptic Drugs in Control Groups 1 and 2.*
Type of Malformation
No. with  
Malformation†
No. with Malformation 
Exposed to Valproic 
Acid Monotherapy
Adjusted Odds Ratio for 
Valproic Acid Monotherapy 
vs. No AED (95% CI)‡
Adjusted Odds Ratio for 
Valproic Acid Monotherapy 
vs. Other AED Monotherapy 
(95% CI)‡
Nervous system
Spina bifida 2,046 27
Control group 1 12.7 (7.7–20.7) 5.7 (2.6–12.3)§
Control group 2 16.3 (8.0–33.4) 3.5 (1.2–10.0)§
Microcephaly¶ 696 2
Control group 1 2.5 (0.3–9.7)‖ 1.6 (0.1–14.7)‖
Control group 2 2.6 (0.3–11.6)‖ 1.0 (0.1–9.8)‖
Heart
Ventricular septal defect 11,711 19
Control group 1 1.6 (0.9–2.7) 2.2 (1.1–4.4)§
Control group 2 1.8 (0.8–3.9) 1.5 (0.6–4.2)§
Atrial septal defect 8,267 19
Control group 1 2.5 (1.4–4.4) 3.2 (1.5–7.0)§
Control group 2 3.3 (1.4–7.4) 2.4 (0.8–7.0)§
Tetralogy of Fallot 960 3
Control group 1 2.8 (0.6–8.6)‖ 1.5 (0.2–7.9)‖
Control group 2 2.8 (0.5–10.4)‖ 0.9 (0.1–5.5)‖
Pulmonary-valve atresia 311 1
Control group 1 2.8 (0.1–16.7)‖ 2.4 (0.0–193.6)‖
Control group 2 2.9 (0.1–19.5)‖ 1.5 (0.0–120.7)‖
Hypoplastic right heart 85 0
Control group 1 — —
Control group 2 — —
Cleft palate 2,244 13
Control group 1 5.2 (2.8–9.9) 3.0 (1.2–7.4)§
Control group 2 5.2 (2.2–12.3) 1.9 (0.6–5.9)§
Diaphragmatic hernia 754 2
Control group 1 2.3 (0.3–9.0)‖ 1.2 (0.1–8.9)‖
Control group 2 2.4 (0.3–10.7)‖ 0.7 (0.1–6.1)‖
Gastroschisis 798 1
Control group 1 1.1 (0.0–6.5)‖ 1.2 (0.0–24.0)‖
Control group 2 1.1 (0.0–7.6)‖ 0.7 (0.0–15.6)‖
Hypospadias (male outcome 
only)
5,395 32
Control group 1 4.8 (2.9–8.1) 6.7 (2.9–15.2)§
Control group 2 6.3 (2.6–15.2) 4.1 (1.1–15.0)§
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tic drug as compared with no such exposure have 
shown that the risk is significantly higher with 
exposure to valproic acid than with exposure to 
other antiepileptic drugs. Furthermore, these stud-
ies have suggested increased risks of malforma-
tions in general in association with higher doses 
of valproic acid as compared with lower dos-
es.13,15-17 Since our data set does not include dose 
information, we were not able to address this 
question.
Previous studies of valproic acid monotherapy 
during the first trimester and the risk of specific 
malformations, other than spina bifida,27,28 have 
generally been limited by relatively small samples 
or potential selection bias, since they have not 
been population-based.11,13,15,17 Our results are 
in line with those of another large, population-
based, case–control registry study of congenital 
malformations in which the control group had 
malformations; specific associations were reported 
between valproic acid exposure and spina bifida, 
hypospadias, malformations of the brain and 
heart, and limb-reduction malformations.26
A recent study showed that children exposed 
to valproic acid in utero were more likely to have 
impaired cognitive function at 3 years of age than 
children exposed in utero to other antiepileptic 
drugs.29 The American Academy of Neurology has 
recommended avoiding valproic acid in pregnan-
cy, if possible, on the basis of evidence that ex-
posure to valproic acid is associated with an in-
creased risk of major congenital malformations 
and poor cognitive outcomes and confers a higher 
risk than that associated with exposure to other 
antiepileptic drugs.9
For malformations seen less frequently, our 
study was able to rule out very large risks but not 
smaller risks. The confidence limits were wide, 
showing that even a study of nearly 4 million preg-
nancies is not enough to address a potentially 
moderate association between rare malformations 
and relatively rare drug exposures.
A limitation of our study, as discussed above, 
is the lack of information on potential confound-
ers. Furthermore, we used controls with mal-
formations instead of those without malforma-
tions, since EUROCAT does not include detailed 
population-based data on pregnancy outcomes 
without malformations. An advantage of using 
controls with malformations is that it minimizes 
the potential for recall bias and other possible 
sources of differential exposure ascertainment, 
although such biases would be unlikely to influ-
ence the results, since most drug information 
was recorded before the outcome of pregnancy 
was known. Use of controls with malformations 
Table 3. (Continued.)
Type of Malformation
No. with  
Malformation†
No. with Malformation 
Exposed to Valproic 
Acid Monotherapy
Adjusted Odds Ratio for 
Valproic Acid Monotherapy 
vs. No AED (95% CI)‡
Adjusted Odds Ratio for 
Valproic Acid Monotherapy 
vs. Other AED Monotherapy 
(95% CI)‡
Limb
Clubfoot¶ 3,676 6
Control group 1 1.6 (0.7–3.7) 1.3 (0.5–3.9)§
Control group 2 2.2 (0.8–6.7) 1.2 (0.3–4.7)§
Polydactyly 3,500 9
Control group 1 2.2 (1.0–4.5) 7.1 (1.8–28.4)§
Control group 2 2.4 (0.9–6.4) 4.4 (0.8–22.6)§
Craniosynostosis 520 4
Control group 1 6.8 (1.8–18.8)‖ 4.9 (0.7–55.2)‖
Control group 2 7.0 (1.7–22.9)‖ 2.9 (0.4–35.8)‖
* Control group 1 included registrations without chromosomal abnormalities, and control group 2 registrations with chromosomal abnormal-
ities. For the number of cases with no exposure to valproic acid, see Section 3 in the Supplementary Appendix, available with the full text of 
this article at NEJM.org. 
† A case or control may have been counted in more than one subgroup.
‡ Odds ratios were adjusted for reporting registry, birth year, and maternal age unless otherwise indicated.
§ Odds ratios were adjusted for birth year and maternal age only. 
¶ Microcephaly and clubfoot occurred without spina bifida.
‖ Odds ratios were not adjusted because of the small number of exposed cases.
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for comparison could lead to a conservative esti-
mation of the risk associated with valproic acid 
exposure if some of the malformations present 
in the control group were also associated with 
this exposure; however, by design we excluded 
from the control groups malformations previ-
ously associated with valproic acid exposure. The 
rate of valproic acid exposure was similar in the 
two control groups (1.1 per 1000), and the point 
estimates for the control group with chromo-
somal abnormalities were similar but slightly 
higher than those for the control group without 
chromosomal abnormalities in comparisons of 
exposure to an antiepileptic drug with no such 
exposure. We therefore concluded that there was 
likely to be little or no contamination of our 
control groups with malformation types associ-
ated with valproic acid exposure and that under-
estimation of odds ratios because of this bias was 
unlikely.
Although the relative risks of several malfor-
mations were increased in association with expo-
sure to valproic acid during the first trimester, it 
should be recognized that the absolute rates of 
specific malformations are low, and the majority 
of children born to mothers who take valproic 
acid do not have malformations. For example, the 
baseline prevalence of spina bifida is about 0.5 
cases per 1000 (see Section 2 in the Supplemen-
tary Appendix). We calculated an adjusted odds 
ratio of 12.7 for the risk of spina bifida when 
comparing exposure to valproic acid with no 
exposure to an antiepileptic drug (Table 3); the 
absolute risk of having a child with spina bifida 
is approximately 0.6% in cases of exposure to val-
proic acid monotherapy during the first trimes-
ter. The estimated absolute risks for the other 
five malformations after exposure are as follows: 
atrial septal defect, 0.5%; cleft palate, 0.3%; hy-
pospadias, 0.7%; polydactyly, 0.2%; and cranio-
synostosis, 0.1%. In determining whether to pre-
scribe antiepileptic drugs, as well as which drug 
to prescribe, several factors must be taken into 
account, among them the goal of optimizing 
seizure control in the individual patient. The 
decision should be made by the patient and her 
clinician after consideration of the benefits and 
risks of various agents.
In summary, we found that exposure to val-
proic acid during the first trimester was associated 
with increased risks of six specific malformations, 
as compared with no exposure to antiepileptic 
drugs, and the risks of five of these six malforma-
tions remained significantly increased when we 
compared valproic acid exposure with exposure to 
other antiepileptic drugs. Our findings provide 
further support for the recommendation of the 
American Academy of Neurology to avoid the use 
of valproic acid, if possible, in pregnant women.9 
Since switching drugs during or just before preg-
nancy is difficult, the risks associated with val-
proic acid use should be routinely considered in 
choosing therapy for women with childbearing 
potential.
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Megdeburg), A. Wiesel (Johannes Gutenberg Universität, Geburtenregister Mainzer Modell), Germany; M. O’Mahony (Health Service 
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